CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants have an exercise price of $1.32 per share, are immediately exercisable upon iss ...

An address suspected to be associated with BitMEX co-founder Arthur Hayes received 1.1253 million LIDO and 3,033.14 AAVE from Flowdesk today, with a combined value of approximately 2.05 million USD, suggesting a possible OTC purchase of Ethereum DeFi blue-chip tokens. https://t.co/umEMaxCULB ...

CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants will have an exercise price of $1.32 per share, will be immediately exercisable ...

Core Insights - Citius Oncology has executed a distribution services agreement with Cencora to enhance its commercial infrastructure for the FDA-approved immunotherapy LYMPHIR [1][2][3] - The agreement aims to expand Citius Oncology's distribution network, ensuring product availability upon launch and supporting long-term scalability [2][3] - LYMPHIR is indicated for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is a targeted immune therapy that has shown antitumor activity [4][5] Company Overview - Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, focusing on developing and commercializing novel targeted oncology therapies [29][30] - The FDA approved LYMPHIR in August 2024, with an estimated initial market exceeding $400 million, indicating significant growth potential in an underserved market [29][30] - Citius Pharmaceuticals also has a late-stage pipeline that includes other critical care products, demonstrating a diverse portfolio [30] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that targets IL-2 receptors, leading to cell death in tumors expressing these receptors [4][5] - The product is indicated for adult patients with r/r Stage I-III CTCL after at least one prior systemic therapy [8][29] - The drug has received regulatory approval in Japan for CTCL and peripheral T-cell lymphoma (PTCL) prior to its FDA approval [5]

Core Insights - Ashland Inc. is implementing a $60 million plan to optimize its manufacturing network, which includes closing its Parlin, NJ facility and relocating hydroxyethyl cellulose (HEC) production to Hopewell, VA [1][7] - The company aims to enhance operational efficiency, reduce production costs, and achieve HEC optimization targets on schedule through this transition [2][3] - Ashland has completed its portfolio optimization and a $30 million restructuring plan, which will accelerate cost savings and improve profitability [3][5] Manufacturing Network Changes - The closure of the Chatham, NJ site will also occur, with microbial protection production being transferred to Freetown, MA, consolidating smaller operations into larger, more efficient sites [2][7] - Investments have been made in the Hopewell facility to expand both capacity and capabilities, reinforcing Ashland's core technologies [4][5] Financial Performance and Market Position - The newly streamlined HEC production network is positioned to meet global demand, with operations in the United States, Europe, and China [5] - Ashland's shares have decreased by 41.4% over the past year, contrasting with a 3.7% rise in the industry [6]

Core Insights - Ashland Inc. is implementing a $60 million manufacturing network optimization plan to enhance operational consistency and profitability, which includes closing its Parlin, New Jersey facility and transferring hydroxyethyl cellulose (HEC) production to Hopewell, Virginia [1][2] - The company is also consolidating its microbial protection production from Chatham, New Jersey to Freetown, Massachusetts, aiming to improve cost efficiency across its manufacturing sites [1][2] - The optimization plan is expected to strengthen core technologies, including vinyl pyrrolidone and derivatives (VP&D) and HEC, with the Hopewell facility receiving increased investments to expand capacity [2][3] Manufacturing Strategy - The completion of the HEC plans is a vital component of Ashland's overall savings initiative, with the newly consolidated HEC network capable of supporting demand in the United States, Europe, and China [2] - Ashland is focused on identifying and accelerating productivity within its plant network to drive savings beyond the $60 million target [2][3] - The company emphasizes a strategic approach to innovation and organic growth, allowing for cost-effective repurposing of assets while maintaining operational efficiency [5] Investment and Growth - Significant investments have been made in various regions, including Ireland, the United States, Brazil, and China, to enhance capabilities in injectables, tablet coatings, and microbial protection [3] - Ashland is also in the process of building a tablet coating plant in India, further expanding its global footprint [3] - The company showcased new patented technologies during a recent Innovation Day, aimed at unlocking new markets with differentiated performance [4]

Core Insights - Incyte's Monjuvi (tafasitamab-cxix) received FDA approval for a new indication in combination with Rituxan and Revlimid for treating adult patients with relapsed or refractory follicular lymphoma (FL) [1][2][8] - This marks the second approved indication for Monjuvi in the U.S. and establishes it as the first CD19- and CD20-targeted immunotherapy combination approved for FL [2][8] - The approval was based on the pivotal phase III inMIND study, which demonstrated significant improvement in progression-free survival (PFS) [6][7][8] Company Performance - Incyte's shares have decreased by 1.1% year-to-date, while the industry has seen a decline of 4.8% [5] - Monjuvi's revenues reached $29.6 million in Q1 2025, reflecting a 24% year-over-year increase, with expectations for further sales growth due to the expanded label [10] Clinical Data - The inMIND study showed a median PFS of 22.4 months for patients treated with Monjuvi, Rituxan, and Revlimid, compared to 13.9 months in the control group [9]

PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal. GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchici ...

Core Viewpoint - Class action lawsuits have been filed against Viatris Inc. and Canopy Growth Corporation, alleging that both companies made materially false and misleading statements regarding their business operations and financial prospects during specified class periods [2][3]. Viatris Inc. (NASDAQ: VTRS) - Class Period: August 8, 2024 – February 26, 2025 - Lead Plaintiff Deadline: June 3, 2025 - Allegations include failure to disclose the significant impact of a failed FDA inspection at the Indore facility, which affected the company's ability to manufacture and ship key products, particularly Lenalidomide [2]. - The complaint states that the positive statements made by the defendants regarding the company's business were materially misleading and lacked a reasonable basis [2]. Canopy Growth Corporation (NASDAQ: CGC) - Class Period: May 30, 2024 – February 6, 2025 - Lead Plaintiff Deadline: June 3, 2025 - Allegations include incurring significant costs related to the production of Claybourne pre-rolled joints and the Storz & Bickel vaporizer devices, which negatively impacted the company's gross margins and overall financial results [3]. - The complaint asserts that the defendants overstated the efficacy of cost reduction measures and downplayed issues affecting gross margins, leading to materially misleading statements about the company's business [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth projections [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Viatris [2]. - The complaint alleges that Viatris and its executives made false statements and failed to disclose significant risks related to a failed FDA inspection at its Indore facility, which adversely affected the company's financial outlook [4]. - The class action lawsuit claims that Viatris downplayed the impact of the FDA inspection and the resulting remediation efforts, which significantly hindered the company's ability to manufacture and ship key products [4]. Group 2: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for Q4 and full fiscal year 2024, attributing below-expectation guidance to the financial impact from the Indore facility's warning letter and import alert [5]. - Following the announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [6].